NSE: DIVISLAB · 9 November 2026
- Divi's Laboratories Ltd shares advanced 4.22% during the session, trading near the upper end of the day's range between a low of ₹11,071.0 and a high of ₹11,824.0.
- Divi's Laboratories Limited submitted to the stock exchanges its unaudited financial results for the period ended September 30, 2026. The company subsequently hosted an analyst and investor conference call on the same day to discuss its operating performance and financial outcomes.
- Trading volume was 3.78 times the 20-day average daily volume.
Why is Divi S Laboratories share price rising on 9 November 2026?
Divi's Laboratories Ltd shares advanced 4.22% during the session, trading near the upper end of the day's range between a low of ₹11,071.0 and a high of ₹11,824.0.
The broader market benchmark Nifty ended little changed with a 0.06% gain, whereas the Nifty Pharma sector index recorded a strong 3.42% increase. Divi's Laboratories outperformed both the broader market and its sectoral benchmark, building on solid medium-term momentum that includes a 5-day return of 16.29% and a 20-day return of 23.83%.
Company filings indicate that Divi's Laboratories submitted its unaudited financial results for the quarter ended September 30, 2026, on November 7, 2026, alongside an earnings call conducted on the same day.
25.86 lakh shares traded by 9 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 6.85 lakh shares (3.78 times). The five-day average daily volume was 7.57 lakh shares. Separately, the NSE report for 9 November 2026 showed 7.88 lakh shares delivered, representing 30.49% of that day’s traded volume. The same report recorded 281,051 trades.
Divi's Laboratories gained 4.22% on massive volume that exceeded 3.7 times its 20-day average, outperforming a rising Nifty Pharma sector. While recent quarterly financial filings provide ongoing fundamental context, the sharp price and volume expansion reflects strong institutional and cash-market participation following a robust multi-week return profile.
Latest Company Developments
Divi's Laboratories Limited submitted to the stock exchanges its unaudited financial results for the period ended September 30, 2026. The company subsequently hosted an analyst and investor conference call on the same day to discuss its operating performance and financial outcomes.
Periodic financial reports provide critical updates on revenue growth, profit margins, and cost structures that guide investor valuation.
The company successfully convened its 36th Annual General Meeting through video conferencing, where shareholders approved the audited financial statements for the financial year ended March 31, 2026, and a final dividend of ₹30 per equity share. Management also outlined strategic updates regarding capacity expansions at Unit 3 and the long-term outlook for specialized peptide therapeutics and custom manufacturing.
The meeting formalised capital returns to shareholders and reaffirmed management's long-term operational roadmap in high-barrier APIs and CDMO services.
The company announced the cessation of Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects), due to retirement effective from the close of business hours on July 31, 2026.
Management transitions in key operational verticals mark leadership changes within procurement and infrastructure project execution.
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.66% on 30 September 2026. This compares with 13.87% on 30 June 2026, a change of +0.79 percentage points.
The filing reported 49 MF/UTI holders.
What to Watch Next
- Execution progress and capacity ramp-up at the Greenfield Unit 3 facility near Kakinada
- Sustained delivery volumes and cash market participation relative to the 20-day average volume of 3.78x
- Management commentary and updates on custom synthesis and high-barrier API demand
- Regulatory audit outcomes and compliance status across manufacturing facilities
Other Dated Coverage
- Divi S Laboratories Share Price Today: Why DIVISLAB Is Falling 3.12% | 23 October 2026 — 23 October 2026
- Divi S Laboratories Share Price Today: Why DIVISLAB Is Rising 0.40% | 7 October 2026 — 7 October 2026
- Why Divi's Laboratories Shares Are Rising 3.85% Today | 6 October 2026 — 6 October 2026
More Divi S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Divi S Laboratories company news?
Divi's Laboratories Limited submitted to the stock exchanges its unaudited financial results for the period ended September 30, 2026. The company subsequently hosted an analyst and investor conference call on the same day to discuss its operating performance and financial outcomes.
How strong was Divi S Laboratories’s trading volume?
25.86 lakh shares traded, 3.78 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.